Kancera provides operational update and announces issue of shares according to agreement with Global Corporate Finance
In 2018, Kancera applied for patent protection for two more inventions within the fractalkine project. Together, these patent applications, which are now entering the international phase, have laid the foundation for the new drug candidate KAND145.
The new issue to GCF takes place in accordance with the agreement with a discount of 9% based on the share price. Through the rights issue, which is supported by the authorization of the Annual General Meeting on May 27, 2019, the number of shares in Kancera increases to 202,825,492.
About Kancera AB (publ)
Kancera develops drugs that counteract damage during acute and chronic inflammation. The Fractalkine blocker KAND567 is primarily developed to effectively and selectively reduce the inflammation of the heart and vessels following a heart attack and is expected to enter the clinical phase II study in 2019. Since scientific studies have shown elevated levels of fractalkine not only in heart attacks but also in inflammatory diseases and certain forms of cancer, there are several possible development opportunities for the fractalkine blockers KAND567 and KAND145. Kancera also develops preclinical drug projects against cancer aimed at stopping survival signals in the cancer cell and preventing the cancer cell's ability to be repaired. Kancera operates at Karolinska Institutet Science Park in Stockholm. The share is traded on Nasdaq First North. FNCA Sweden AB (tel. 08-528 00 399, email@example.com) is the company's Certified Adviser. MD PhD Charlotte Edenius, MD PhD Anders Gabrielsen, Professor Carl-Henrik Heldin and Professor Håkan Mellstedt are all scientific advisors and board members of Kancera AB.
For further information, contact:
Thomas Olin, CEO: +46-(0)735-20 40 01
Kancera AB (publ)
Karolinska Institutet Science Park
SE 171 48 Solna
Welcome to visit our home-page: www.kancera.comBack